Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
Abstract Ovarian cancer has a poor cure rate and rates of relapse are high. Current recurrence detection is limited by non-specific methods such as blood testing and ultrasound. Based on reports that human epididymis four (HE4) / creatinine (CRE) ratios found in urine are elevated in ovarian cancers...
Guardado en:
Autores principales: | Emily C. Kight, Iftak Hussain, Audrey K. Bowden, Frederick R. Haselton |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a73edc14b2374ee8aa07670b68bbbf70 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Thoracic surgery for ovarian cancer recurrence
por: V.V. Boyko, et al.
Publicado: (2017) -
BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
por: Weiya Z Wysham, et al.
Publicado: (2012) -
Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
por: Qin Jiang, et al.
Publicado: (2021) -
Identification of a six-lncRNA signature associated with recurrence of ovarian cancer
por: Kai Yang, et al.
Publicado: (2017) -
Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Lili Gao, et al.
Publicado: (2021)